Company research
ENANTA PHARMACEUTICALS INC
CIK 1177648Updated Sep 26, 2026
SecurityENTA · NASDAQ · equity
ENTA price & chart
Loading TradingView…
NASDAQ:ENTA on TradingView ↗About the company
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline
In the news
No coverage from other publishers is available.
Recent filings
SCHEDULE 13G/A filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Entry into a Material Definitive Agreement
Items 1.01, 9.01
424B5 filing
Show 5 more recent filings
Other Events
Items 8.01
Regulation FD Disclosure
Items 7.01, 9.01
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 280,732,000Source | 376,652,000Source | 462,275,000Source | 375,410,000Source |
| Property, Plant and Equipment, NetUSD | 35,395,000Source | 32,688,000Source | 11,919,000Source | 6,173,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 32,298,000Source | 37,233,000Source | 85,388,000Source | 43,994,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 6,882,000Source | 6,646,000Source | 8,614,000Source | 20,318,000Source |
| Assets, CurrentUSD | 204,336,000Source | 299,852,000Source | 422,791,000Source | 311,713,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,590,000Source | 12,413,000Source | 13,263,000Source | 13,445,000Source |
| Operating Lease, Right-of-Use AssetUSD | 37,549,000Source | 40,658,000Source | 22,794,000Source | 23,575,000Source |
| Other Assets, NoncurrentUSD | 92,000Source | 94,000Source | 803,000Source | 696,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 216,015,000Source | 247,838,000Source | 245,540,000Source | 54,076,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 214,000Source | 212,000Source | 211,000Source | 208,000Source |
| Retained Earnings (Accumulated Deficit)USD | -404,929,000Source | -323,040,000Source | -206,995,000Source | -73,179,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -339,000Source | 302,000Source | -1,174,000Source | -3,724,000Source |
| Stockholders' Equity Attributable to ParentUSD | 64,717,000Source | 128,814,000Source | 216,735,000Source | 321,334,000Source |
| Additional Paid in Capital, Common StockUSD | 469,771,000Source | 451,340,000Source | 424,693,000Source | 398,029,000Source |
| Liabilities and EquityUSD | 280,732,000Source | 376,652,000Source | 462,275,000Source | 375,410,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 48,555,000Source | 57,535,000Source | 62,787,000Source | 29,827,000Source |
| Operating Lease, Liability, CurrentUSD | 3,146,000Source | 1,524,000Source | 5,275,000Source | 2,891,000Source |
| Accounts Payable, CurrentUSD | 1,948,000Source | 8,002,000Source | 4,097,000Source | 6,000,000Source |
| Operating Lease, Liability, NoncurrentUSD | 54,757,000Source | 53,943,000Source | 21,238,000Source | 22,372,000Source |
| Other Liabilities, NoncurrentUSD | 260,000Source | 231,000Source | 663,000Source | 454,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 12,751,000Source | 13,547,000Source | 18,339,000Source | 20,936,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -81,889,000Source | -116,045,000Source | -133,816,000Source | -121,755,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 18,565,000Source | 26,795,000Source | 28,216,000Source | 26,969,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 236,000Source | -1,968,000Source | -11,704,000Source | -3,258,000Source |
| Increase (Decrease) in Accounts PayableUSD | -1,311,000Source | -414,000Source | -1,151,000Source | -4,634,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -19,272,000Source | -78,764,000Source | -103,154,000Source | -84,782,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 40,347,000Source | 58,235,000Source | -53,578,000Source | 54,897,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 12,896,000Source | 17,948,000Source | 9,058,000Source | 2,125,000Source |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 277,000Source | 294,000Source | 3,757,000Source | 1,229,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -26,618,000Source | -27,626,000Source | 198,126,000Source | 20,033,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -5,543,000Source | -48,155,000Source | 41,394,000Source | -9,852,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 8,794,000Source | 11,710,000Source | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 18,565,000Source | 26,795,000Source | 28,216,000Source | 26,969,000Source |
| Debt Securities, Available-for-sale, Allowance for Credit Loss, Not Previously RecordedUSD | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of AssetsUSD | -6,000Source | -16,000Source | -150,000Source | — |
| General and Administrative ExpenseUSD | 43,933,000Source | 57,850,000Source | 52,887,000Source | 45,482,000Source |
| Income Tax Expense (Benefit)USD | -1,660,000Source | -1,743,000Source | 2,821,000Source | -433,000Source |
| InterestExpenseNonoperatingUSD | 7,681,000Source | 10,940,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -81,889,000Source | -116,045,000Source | -133,816,000Source | -121,755,000Source |
| Nonoperating Income (Expense)USD | 1,800,000Source | 3,903,000Source | 6,212,000Source | 1,656,000Source |
| Proceeds from Stock Options ExercisedUSD | 145,000Source | 147,000Source | 2,208,000Source | 21,262,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 65,324,000Source | 67,635,000Source | 79,204,000Source | 86,160,000Source |
| Operating Income (Loss)USD | -85,349,000Source | -121,691,000Source | -137,207,000Source | -123,844,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -83,549,000Source | -117,788,000Source | -130,995,000Source | -122,188,000Source |
| Income Tax Expense (Benefit)USD | -1,660,000Source | -1,743,000Source | 2,821,000Source | -433,000Source |
| Net Income (Loss) Attributable to ParentUSD | -81,889,000Source | -116,045,000Source | -133,816,000Source | -121,755,000Source |
| Earnings Per Share, BasicUSD per share | -3.84Source | -5.48Source | -6.38Source | -5.91Source |
| Earnings Per Share, DilutedUSD per share | -3.84Source | -5.48Source | -6.38Source | -5.91Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 21,336Source | 21,157Source | 20,969Source | 20,603Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 21,336Source | 21,157Source | 20,969Source | 20,603Source |
| Interest Expense (non-operating)USD | 7,681,000Source | 10,940,000Source | — | — |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | 150,673,000Source | 189,326,000Source | 216,411,000Source | 210,004,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 4,586,000Source | 2,336,000Source | 2,371,000Source | 2,973,000Source |
| General and Administrative ExpenseUSD | 43,933,000Source | 57,850,000Source | 52,887,000Source | 45,482,000Source |
| Interest ExpenseUSD | — | — | 5,148,000Source | — |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | 11,360,000Source | 1,573,000Source |
| Investment Income, NetUSD | 9,442,000Source | 14,770,000Source | — | — |
| Nonoperating Income (Expense)USD | 1,800,000Source | 3,903,000Source | 6,212,000Source | 1,656,000Source |
| Research and Development ExpenseUSD | 106,740,000Source | 131,476,000Source | 163,524,000Source | 164,522,000Source |
Filing attachments
enta-ex99_1.htm · 8-K · 2026-08-10
EX-99.1 2 enta-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026 • Dosing Initiated in LOTUS, a Phase 2b Pediatric Trial of Zelicapavir; Topline Data Expected in 2027 • On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027 • On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily K…
Read attachment ↗d159604dex991.htm · 8-K · 2026-06-18
EX-99.1 2 d159604dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV) Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data Expected in 2027 WATERTOWN, Mass., …
Read attachment ↗d159604dex992.htm · 8-K · 2026-06-18
EX-99.2 3 d159604dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Zelicapavir Update June 18, 2026 1 Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statements contained herein that are not statements of historical facts may be deemed…
Read attachment ↗enta-ex99_1.htm · 8-K · 2026-05-11
EX-99.1 2 enta-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 • Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 • Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory Syncytial Virus (RSV) • On Track to File an IND f…
Read attachment ↗enta-ex99_1.htm · 8-K · 2026-02-09
EX-99.1 2 enta-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 • Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) • Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to Select a Development Candidate in 2H 2026 • On T…
Read attachment ↗enta-ex99_1.htm · 8-K · 2025-11-17
EX-99.1 2 enta-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended September 30, 2025 • Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models • Announces EDP-978, an Oral, Once-Daily KIT Inhibitor Clinical Candidate with Plans to F…
Read attachment ↗